Rybelsus New Formulation: What You Need to Know

Rybelsus, the oral semaglutide tablet licensed for type 2 diabetes in adults, has attracted renewed interest following the MHRA authorisation of Wegovy 25 mg tablets in June 2026. Searches for a 'rybelsus new formulation' often reflect curiosity about this development, but the two products are distinct, with different indications, dose strengths and patient populations. This article explains how Rybelsus works, what side effects to monitor, how to take it correctly, and what NHS or private access currently looks like in the UK.

What is the new Rybelsus formulation and how does it differ?

Wegovy 25 mg tablets are not a reformulation of Rybelsus but a separate MHRA-authorised product; both contain semaglutide but have different indications, dose strengths and titration schedules and must not be treated as interchangeable.

The term 'new Rybelsus formulation' is a common search phrase, but it is important to be clear: Wegovy 25 mg tablets are not a reformulation of Rybelsus. They are an entirely separate licensed product. Both contain semaglutide, but they have different licensed indications, different dosing schedules and different patient populations, and they should not be treated as interchangeable.

Rybelsus is an oral semaglutide tablet licensed for the management of type 2 diabetes in adults, available in 3 mg, 7 mg and 14 mg strengths.^[3][4] Wegovy 25 mg tablets, authorised by the MHRA on 11 June 2026, are indicated specifically for chronic weight management and should be reviewed against their own Summary of Product Characteristics (SmPC) and Patient Information Leaflet (PIL), not against the Rybelsus label.^[1][2]

Both products contain semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, and both use an absorption-enhancing technology to allow the peptide to cross the gut wall.^[3][13] However, the dose strengths and titration schedules differ substantially between the two products, reflecting their separate development programmes and regulatory submissions. Patients and healthcare professionals should always refer to the specific product's SmPC and PIL rather than assuming the two products are interchangeable.

If you have been prescribed Rybelsus for type 2 diabetes and have questions about whether a different oral semaglutide product might be relevant to your care, this is a conversation to have with your GP or diabetes specialist, who can review your individual clinical circumstances and current prescribing guidance. You should not switch between oral semaglutide products without clinician guidance.

What side effects should you watch for with Rybelsus?

The most common side effects are gastrointestinal, including nausea, vomiting and diarrhoea; acute pancreatitis has been reported and patients should seek urgent medical advice if they develop persistent severe abdominal pain.

Rybelsus (oral semaglutide) shares a side-effect profile broadly consistent with other GLP-1 receptor agonists, with gastrointestinal effects being the most commonly reported. These include nausea, vomiting, diarrhoea, constipation and abdominal discomfort, and they tend to be most pronounced during the dose escalation phase, often settling as the body adjusts over several weeks.

Acute pancreatitis has been reported with semaglutide, including post-marketing reports of necrotising pancreatitis and reports with a fatal outcome.^[8][3] Patients should be aware of the warning signs, which include persistent and severe abdominal pain that may radiate to the back. If these symptoms occur, treatment should be stopped and medical advice sought promptly by contacting your GP or, if symptoms are severe and sudden, attending A&E. If pancreatitis is confirmed, Rybelsus should not be restarted. Patients with a history of pancreatitis should discuss this with their prescriber before starting treatment.

For people with pre-existing diabetic eye disease, particularly those with pre-proliferative or proliferative retinopathy, rapid improvement in blood glucose control has been associated with transient worsening of diabetic retinopathy. This risk applies specifically to those with pre-existing diabetic eye conditions, and regular ophthalmology review is advisable for this subgroup.

When Rybelsus is used alongside a sulfonylurea (such as gliclazide) or insulin, the risk of hypoglycaemia increases.^[7][3] Your prescriber may reduce the dose of the sulfonylurea or insulin when starting Rybelsus. If you experience symptoms of low blood sugar, such as shakiness, sweating, confusion or palpitations, follow your usual hypoglycaemia management plan and contact your care team.

Rybelsus is not recommended during pregnancy or breastfeeding.^[3][7] If you are pregnant, planning a pregnancy or breastfeeding, you should discuss this with your prescriber before starting or continuing treatment, as alternative management of your diabetes may be needed.

Suspected side effects from Rybelsus can be reported to the MHRA via the Yellow Card scheme at yellowcard.^[15]mhra.gov.uk. Reporting helps the MHRA monitor the safety of medicines in real-world use. If you are taking Rybelsus as part of a clinical trial, adverse events should be reported to the trial team under the study protocol.

How Rybelsus works and how to take it

Rybelsus uses SNAC absorption-enhancing technology to deliver semaglutide through the gastric mucosa; it must be taken on an empty stomach with plain water and patients must wait at least 30 minutes before eating or taking other medicines.

Semaglutide, the active ingredient in Rybelsus, works by mimicking the action of the naturally occurring hormone GLP-1, which is released from the gut in response to food. GLP-1 receptor agonists stimulate insulin secretion in a glucose-dependent manner, meaning they promote insulin release when blood glucose is elevated but have a diminishing effect as glucose levels normalise, which reduces the risk of hypoglycaemia compared with some other diabetes medicines.

Oral delivery of semaglutide presents a pharmacological challenge because peptides are typically broken down in the gastrointestinal tract before they can be absorbed. Rybelsus addresses this by co-formulating semaglutide with sodium N-(8-(2-hydroxybenzoyl)amino)caprylate (SNAC), an absorption enhancer that protects the peptide from enzymatic degradation and facilitates its absorption through the gastric mucosa.^[6][14] This is why Rybelsus must be taken on an empty stomach with a small amount of plain water only, swallowed whole without crushing or splitting, and why patients must wait at least 30 minutes before eating, drinking anything other than plain water, or taking other oral medicines, to allow adequate absorption.^[3][7]

Beyond its effects on insulin secretion, semaglutide also suppresses glucagon release, slows gastric emptying and acts on appetite-regulating centres in the brain, contributing to reduced caloric intake.^[18][19] In the context of type 2 diabetes management, these combined mechanisms support both glycaemic control and, in many patients, modest reductions in body weight. The precise magnitude of effect varies between individuals and is influenced by adherence to dosing instructions, diet and other lifestyle factors.

Oral and injectable semaglutide products should not be used concurrently unless specifically directed by a specialist. If you have any questions about how to take Rybelsus correctly, refer to the PIL supplied with your medicine or speak to your pharmacist or prescriber.

Is the new formulation available on the NHS or prescription in the UK?

Rybelsus may be prescribed on the NHS subject to NICE guidance and local ICB commissioning decisions; Wegovy 25 mg tablets have separate regulatory status and their NHS availability will depend on future NICE appraisal and ICB decisions.

Rybelsus (oral semaglutide for type 2 diabetes) holds a marketing authorisation in the UK and may be prescribed within NHS or private settings, subject to local Integrated Care Board (ICB) commissioning decisions and NICE guidance. NICE has assessed oral semaglutide for type 2 diabetes; patients and clinicians should check the current relevant NICE technology appraisal and local ICB policies for up-to-date eligibility criteria, as NHS availability depends on whether a patient meets those criteria and whether their local ICB has commissioned the treatment.^[17] Patients should discuss eligibility with their GP or diabetes care team.

Wegovy 25 mg tablets, the oral semaglutide product authorised by the MHRA on 11 June 2026 for chronic weight management, is a separate product with its own regulatory status.^[1][2] Its NHS availability will depend on NICE technology appraisal recommendations and subsequent ICB commissioning decisions, which may not follow automatically or immediately from MHRA authorisation.^[16] Patients and clinicians should check current NICE guidance and local ICB policies for the most up-to-date position on NHS access to this product.

For those considering private access to oral or injectable semaglutide options for weight management, a structured clinical consultation is essential to determine which, if any, treatment is appropriate. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where a clinician can assess whether a treatment is clinically appropriate for an individual's circumstances. Any private prescription should come from a registered prescriber following a thorough clinical assessment, and patients should verify that any online pharmacy they use is registered with the GPhC at pharmacyregulation.org or, in Northern Ireland, with the PSNI.

Frequently Asked Questions